Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 1
2016 1
2019 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Long-term sequential deferiprone and deferasirox therapy in transfusion-dependent thalassaemia patients: a prospective clinical trial.
Vitrano A, Ruffo GB, Pepe A, D'Ascola DG, Caruso V, Filosa A, Masera N, Pitrolo L, Rigano P, Cuccia L, Giangreco A, Di Maggio R, Maggio A. Vitrano A, et al. Among authors: giangreco a. Br J Haematol. 2019 Sep;186(6):e209-e211. doi: 10.1111/bjh.16101. Epub 2019 Jul 25. Br J Haematol. 2019. PMID: 31344255 Free article. Clinical Trial. No abstract available.
Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Calvaruso G, Vitrano A, Di Maggio R, Ballas S, Steinberg MH, Rigano P, Sacco M, Telfer P, Renda D, Barone R, Maggio A; Investigators of the Multicenter Randomized Clinical Trial of Deferiprone versus Deferoxamine in Sickle-Cell-Disease. Calvaruso G, et al. Blood Cells Mol Dis. 2014 Dec;53(4):265-71. doi: 10.1016/j.bcmd.2014.04.004. Epub 2014 May 9. Blood Cells Mol Dis. 2014. PMID: 24814618 Clinical Trial.
Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience.
Restivo Pantalone G, Renda D, Valenza F, D'Amato F, Vitrano A, Cassarà F, Rigano P, Di Salvo V, Giangreco A, Bevacqua E, Maggio A. Restivo Pantalone G, et al. Among authors: giangreco a. Br J Haematol. 2010 Jul;150(2):245-7. doi: 10.1111/j.1365-2141.2010.08180.x. Epub 2010 Apr 28. Br J Haematol. 2010. PMID: 20433678 Free article. No abstract available.
Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.
Vitrano A, Calvaruso G, Tesé L, Gioia F, Cassarà F, Campisi S, Butera F, Commendatore V, Rizzo M, Santoro V, Cigna V, Quota A, Bagnato S, Argento C, Fidone C, Schembari D, Gerardi C, Barbiera F, Bellisssima G, Giugno G, Polizzi G, Rosso R, Abbate G, Caruso V, Chiodi E, Gamberini MR, Giorgi B, Putti MC, Filosa A, De Ritis MR, Oliva E, Arcadi N, Fustaneo M, Mistretta L, Di Maggio R, Sacco M, Veronica DS, Giangreco A, Maggio A. Vitrano A, et al. Among authors: giangreco a. Eur J Haematol. 2016 Oct;97(4):361-70. doi: 10.1111/ejh.12740. Epub 2016 Feb 23. Eur J Haematol. 2016. PMID: 26818147